simethicone and Eczema

Eczematous skin disease is a serious work-related illness. Since 1995, reimbursement by insurance companies for treatment of skin diseases has become the largest cost source in some countries. This study was a randomized controlled trial (N = 20) of the efficacy of Pro-Q, a skin protectant product, in the prevention of contact dermatitis from sodium lauryl sulfate and urushiol, the resinous sap of poison ivy and poison oak. Pro-Q was significantly effective in reducing the irritation from sodium lauryl sulfate but did not prevent the allergic reaction to urushiol.

Topics: Administration, Cutaneous; Aerosols; Catechols; Dermatitis, Irritant; Dermatitis, Occupational; Dermatitis, Toxicodendron; Dermatologic Agents; Detergents; Dimethylpolysiloxanes; Double-Blind Method; Eczema; Glycerol; Humans; Irritants; Plants, Toxic; Protective Agents; Simethicone; Sodium Dodecyl Sulfate; Toxicodendron

Topics: Benzalkonium Compounds; Candidiasis; Clinical Trials as Topic; Dermatitis, Seborrheic; Diaper Rash; Drug Combinations; Eczema; Female; Humans; Hydrocortisone; Infant; Intertrigo; Male; Nystatin; Ointments; Pruritus Ani; Pruritus Vulvae; Psoriasis; Scrotum; Silicones; Simethicone; Skin Diseases; Tinea

Attention is drawn to the unwanted side effects of the long-term topical use of steroids on the skin. The topical use of steroids in conditions in which immunological factors are not involved is not necessary. An open clinical evaluation demonstrated that simple protective applications are quite effective in these conditions.

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Child; Dermatitis; Dermatitis, Seborrheic; Drug Evaluation; Eczema; Female; Glucocorticoids; Humans; Ichthyosis; Male; Middle Aged; Psoriasis; Silicones; Simethicone; Skin Diseases